1 of 1
Story summary
- Investors in mainland China increased investments in Hong Kong-listed drug makers, driven by out-licensing deals.
- The Hang Seng Southbound Connect Hong Kong Innovative Drug Index rose about 8% between Feb 2 and Feb 10, 2026.
- CSPC Pharmaceutical Group led gains at 5.52%, followed by Innovent Biologics at 4.98% and Keymed Biosciences at 4.2%.
- Innovent Biologics announced a collaboration with Eli Lilly worth up to US$8.85 billion, including a US$350 million upfront.
